Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Queensland Health
Cerilliant
Boehringer Ingelheim
Fuji
Citi
McKinsey
Farmers Insurance
Johnson and Johnson
Cipla

Generated: October 18, 2017

DrugPatentWatch Database Preview

OXILAN-350 Drug Profile

« Back to Dashboard

Which patents cover Oxilan-350, and when can generic versions of Oxilan-350 launch?

Oxilan-350 is a drug marketed by Guerbet and is included in one NDA.

The generic ingredient in OXILAN-350 is ioxilan. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ioxilan profile page.

Summary for Tradename: OXILAN-350

US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list20
Clinical Trials: see list326
Patent Applications: see list490
Drug Prices:see details
DailyMed Link:OXILAN-350 at DailyMed

Pharmacology for Tradename: OXILAN-350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet
OXILAN-350
ioxilan
INJECTABLE;INJECTION020316-002Dec 21, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OXILAN-350

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Guerbet
OXILAN-350
ioxilan
INJECTABLE;INJECTION020316-002Dec 21, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Deloitte
AstraZeneca
Dow
Novartis
Harvard Business School
Cerilliant
Chinese Patent Office
Cipla
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot